Forward
Cost-Effectiveness of Face-to-Face Smoking Cessation Interventions
Economic and Utilization Outcomes Associated with Choice of Treatment for Venous Thromboembolism in Hospitalized Patients
Managing Prices for Hospital Pharmaceuticals
The Economic Value of Childhood Varicella Vaccination in France and Germany
Federal Sponsorship of Cost-Effectiveness and Related Research in Health Care
MEDICAID DRUG SPENDING AFTER THE MEDICARE MODERNIZATION ACT
EFFECTS OF PATIENTS' BELIEFS ABOUT MEDICATIONS ON NON-ADHERENCE TO CHRONIC MEDICATIONS
WHO WILL REQUEST A SWITCH TO NEW TREATMENT AS A RESULT OF DIRECT-TO-CONSUMER ADVERTISING?
POTENTIALLY INAPPROPRIATE MEDICATION PRESCRIBING FOR ELDERLY AMBULATORY PATIENTS IN REGIONE EMILIA ROMAGNA, ITALY
COST-EFFECTIVENESS OF ONCE WEEKLY EPOETIN ALFA AND DARBEPOETIN ALFA IN TREATING CHEMOTHERAPY-INDUCED ANEMIA
VALUE-FOR-MONEY OF PEMETREXED PLUS CISPLATIN VERSUS CISPLATIN ALONE IN THE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA
ONCOLOGISTS' COST-EFFECTIVENESS THRESHOLDS FOR NEW CANCER THERAPIES
EXPLICIT VALUATION OF PASS-THROUGH TECHNOLOGIES UNDER MEDICARE
WHY DO DIFFERENT MODELS COME TO DIFFERENT CONCLUSIONS?
EVALUATION OF MEDICATION ADHERENCE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
DOES METHOD OF CASE ASCERTAINMENT AFFECT ESTIMATES OF THE PREVALENCE AND SEVERITY OF DEMENTIA IN MEDICARE NURSING HOME RESIDENTS?
CHOOSING BETWEEN SF12/SF-36 PREFERENCE-BASED ALGORITHMS FOR COST-UTILITY ANALYSIS
PARENTERAL PARECOXIB FOLLOWED BY ORAL VALDECOXIB AFTER MAJOR GENERAL SURGERY REDUCES OPIOID CONSUMPTION AND OPIOID-RELATED SYMPTOMS
CARDIOVASCULAR RISK FACTORS AT BASELINE IN USERS OF COXIBS COMPARED TO USERS OF NSAIDS
ECONOMIC EVALUATION OF CONTROLLED-RELEASE OXYCODONE (OXYCONTIN® TABLETS) (CRO) VERSUS OXYCODONE/ACETAMINOPHEN (PERCOCET®) (OXY/APAP) FOR OSTEOARTHRITIS PAIN OF THE HIP OR KNEE
THE COST-EFFECTIVENESS OF ADDING INFLIXIMAB TO USUAL THERAPY IN THE TREATMENT OF PSORIATIC ARTHRITIS
FINANCIAL BARRIERS TO MEDICATION USE IN CHILDREN WITH ASTHMA
CHOLESTEROL GOAL ATTAINMENT AMONG CHD PATIENTS IN HONG KONG
AN EVALUATION OF PHARMACEUTICAL PRICES UNDER THE PHARMACEUTICAL FEDERAL SUPPLY SCHEDULE
FINANCIAL IMPACT OF A PRIOR-AUTHORIZATION RESTRICTION FOR PIMECROLIMUS 1% CREAM IN THE TREATMENT OF ATOPIC DERMATITIS
COMPARISON OF RISK FACTORS FOR BLOOD STREAM CANDIDEMIA AND BACTEREMIA IN HOSPITALIZED PATIENTS
SIMULATION OF A PROPOSED TRIAL TO EVALUATE THE COST-EFFECTIVENESS OF USING A COMBINATION REGIMEN FOR THE TREATMENT OF ACUTE SINUSITIS
COSTS OF DELIVERING ADULT INFLUENZA VACCINATION IN NON-TRADITIONAL SETTINGS
COST EFFECTIVENESS OF HIV TREATMENT INNOVATIONS OF GREATER EFFICACY THAN HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
IS RELIEF WORTH THE RISK? RISK-BENEFIT PREFERENCES FOR TREATMENTS FOR VASOMOTOR SYMPTOMS
NEW WEIGHTS FOR OLD
(For QL3 see page 337)
THE CONTENT VALIDITY OF CLINICIAN DERIVED PATIENT REPORTED OUTCOMES (PRO) MEASURES
QUALITY OF LIFE IN ASTHMA PATIENTS IS AFFECTED BY HOME TELEMANAGEMENT
ASSESSING HEALTH-RELATED QUALITY OF LIFE USING THE SF-12V2 FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
ESTIMATING THE COST-EFFECTIVENESS OF FLUTICASONE PROPIONATE FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
PRESCRIBING PATTERNS IN AMBULATORY CARE CENTERS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
DISCRETE EVENT SIMULATION TO ESTIMATE COST-BENEFIT OF PREVENTING SUDDEN CARDIAC DEATHS WITH AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) VS. AMIODARONE IN FRANCE
LIPID LEVELS AND NCEP ATP-III LDL-CHOLESTEROL GOAL ATTAINMENT IN PATIENTS NEWLY-INITIATED ON ROSUVASTATIN OR ATORVASTATIN
ONE-YEAR COSTS FOR ACUTE CORONARY SYNDROME— AN INTEGRATED HEALTHCARE SYSTEM PERSPECTIVE
CUMULATIVE EXPOSURE TO CYCLOOXYGENASE-2 INHIBITORS AND CARDIOVASCULAR RISK
ECONOMIC BURDEN OF OSTEOPOROSIS-RELATED FRACTURES IN MEDICAID
ECONOMIC IMPACT OF CARDIOVASCULAR EVENTS IN NEWLY DIAGNOSED TYPE-2 DIABETES PATIENTS
IMPACT OF ESTIMATION TECHNIQUE ON MEDICAL COST ESTIMATES FOR OVERACTIVE BLADDER TREATMENTS
COST-UTILITY OF CATHETER ABLATION FOR FIRST-LINE TREATMENT OF ATRIAL FLUTTER
ESTIMATION OF THE FINANCIAL IMPACT OF OBESITY ON THE NATIONAL HEALTH SERVICE AND SOCIETY IN THE UNITED KINGDOM
ECONOMIC CONSEQUENCES OF CHOICE OF DIABETES THERAPY IN A MEDICAID POPULATION
COST-EFFECTIVENESS OF DETECTION OF CAD BY MYOCARDIAL PERFUSION IMAGING IN ASYMPTOMATIC PATIENTS WITH DIABETES
HEART FAILURE RISK OF THIAZOLIDINEDIONES IN A MEDICAID MANAGED CARE POPULATION
PRESCRIPTION DRUG COST-SHARING AND ANTICOAGULANT DRUG USE—UNINTENDED EFFECTS OF THINNER BENEFITS
CHANGES IN ADHERENCE FOLLOWING A CO-PAY CHANGE FOR ASTHMA AND DIABETES THERAPIES
PRESCRIPTION DRUG COPAYMENTS, MAIL ORDER SUBSTITUTION AND STOCKPILING OF MAINTENANCE MEDICATIONS
COX-2 INHIBITOR STEP CARE PROGRAM ON MEDICATION COSTS AND UTILIZATION
ESTIMATING FLEXIBLE SURVIVAL FUNCTIONS FOR USE IN ECONOMIC MODELING
RISK FACTORS AND OUTCOMES OF SURGICAL SITE INFECTIONS IN DIABETICS UNDERGOING CARDIAC SURGERY
9301 COST-EFFECTIVENESS OF LONG-TERM THERAPY WITH CLOPIDOGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION
ASSOCIATION BETWEEN LONG-TERM USE OF NSAIDS/ COX-2 INHIBITORS AND CARDIOVASCULAR RISK–A RETROSPECTIVE ANALYSIS USING THE VETERAN AFFAIRS (VA) DATABASE
COST OF URINARY INCONTINENCE IN GERMANY
TREATMENT OF INSTITUTIONALIZED PATIENTS WITH ALZHEIMER'S DISEASE WITH QUETIAPINE
OVERCOMING SAMPLE-SELECTION CHALLENGES IN ECONOMIC COMPARISONS OF DRUG AND NON-DRUG THERAPY
ECONOMIC EVALUATION OF ONDANSETRON VERSUS DIMENHYDRINATE FOR PREVENTION OF POSTOPERATIVE VOMITING IN CHILDREN
BODY MASS INDEX (BMI) AND TRENDS IN GP CONSULTATIONS AND PRESCRIBING
COMPARISON OF THE COST-EFFECTIVENESS FOR BASAL-BOLUS THERAPY OF TYPE-1 DIABETES USING INSULIN DETEMIR + INSULIN ASPART OR HUMAN INSULIN-BASED REGIMENS IN THE NETHERLANDS
THE EFFECT OF OBESITY ADJUSTMENTS ON COST- EFFECTIVENESS MODELS OF DIABETES PREVENTION
THE IMPACT OF GLYCEMIC CONTROL ON THE INCIDENCE OF DIABETIC COMPLICATIONS
TREATMENT COSTS OF ALZHEIMER'S DISEASE IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM FROM 1995 TO 2002
(For abstract MH2 see page 385)
COSTS OF TREATING CRISIS-PRONE SCHIZOPHRENIA PATIENTS
SUPPORT FOR CLASSIFICATION OF DEPRESSION OUTCOMES INTO LONGITUDINAL PATTERNS
EFFECT OF SECOND-GENERATION ANTIDEPRESSANT DISCONTINUATION ON DEPRESSIVE RELAPSE IN ADULT PATIENTS WITH BIPOLAR DEPRESSION
HEALTH CARE UTILIZATION, COST AND MEDICATION USE AMONG PEDIATRIC ASTHMA PATIENTS
IMPACT OF ANTI-INFLAMMATORY MEDICATION ON ASTHMA COSTS IN A PEDIATRIC POPULATION
A COMPARISON OF ASTHMA MEDICATION USE IN PUBLICLY VERSUS PRIVATELY INSURED CHILDREN WITH ASTHMA
PATTERNS OF PHARMACOTHERAPY UTILIZATION AMONG CHILDREN AND ADOLESCENTS WITH MULTIPLE ASTHMA- RELATED MORBID EVENTS ENROLLED IN A MEDICAID PROGRAM
DRUG COST ANALYSIS OF TREATMENT FOR ASTHMA OUTPATIENTS IN TAIWAN
IMPACT OF ASTHMA KNOWLEDGE ON HEALTH OUTCOMES IN PEDIATRIC PATIENTS
DIRECT AND INDIRECT COST OF ASTHMA IN AN EMPLOYER POPULATION
A DYAD APPROACH TO QUALITY OF LIFE MEASUREMENT IN CHILDREN WITH ASTHMA
CHOOSING AMONG DIFFERENT TYPES OF MATCHING TECHNIQUES
COMPARISON OF ALTERNATIVE STRATEGIES FOR THE DIAGNOSIS OF ACUTE CARDIAC ISCHEMIA IN EMERGENCY DEPARTMENTS
ACUTE CORONARY SYNDROMES
UTILIZATION OF RECOMMENDED DRUG THERAPY IN ACUTE CORONARY SYNDROME
LONG-TERM THIENOPYRIDINE THERAPY IN ACS PATIENTS RESIDING IN THE UNITED KINGDOM
POTENTIAL COST SAVINGS FROM ACUTE CORONARY SYNDROME TREATMENT IMPROVEMENTS
LONG-TERM COST-EFFECTIVENESS OF EARLY AND SUSTAINED DUAL ORAL ANTIPLATELET THERAPY WITH CLOPIDOGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (CREDO TRIAL)
HEALTH CARE RESOURCE UTILIZATION AND COST OF ATRIAL FLUTTER PATIENTS
TOTAL HEALTH CARE COSTS OF PATIENTS WITH CHRONIC NON-VALVULAR ATRIAL FIBRILLATION BEFORE AND AFTER TIA, ISCHEMIC STROKE OR MAJOR BLEED
COST-EFFECTIVENESS OF AMIODARONE TO PREVENT ATRIAL FIBRILLATION AFTER CARDIAC SURGERY
RACE AND GENDER COST DIFFERENCES ASSOCIATED WITH COMORBID ATRIAL FIBRILLATION IN THE HOSPITAL SETTING
QUALITY OF ANTICOAGULATION CONTROL IN PATIENTS WITH ATRIAL FIBRILLATION MANAGED IN ROUTINE MEDICAL CARE IN THE UNITED STATES
DATA CAPTURE VIA INTERACTIVE VOICE RESPONSE SYSTEM IN A NATIONAL STUDY OF ANTICOAGULATION MANAGEMENT
COST-EFFECTIVENESS EVALUATION OF EPLERENONE IN PATIENTS WITH HEART FAILURE FOLLOWING AMI IN GERMANY
MODELING THE ECONOMIC CONSEQUENCES OF CARDIAC RESYNCHRONIZATION THERAPY IN THE UK
POTENTIAL MEDICAL COST OFFSETS OF TREATMENT WITH ISOSRBIDE DINITRATE PLUS HYDRALAZINE IN AFRICAN AMERICANS WITH HEART FAILURE
INCREMENTAL EFFECTS OF CONCURRENT PHARMACOTHERAPEUTIC REGIMENS FOR HEART FAILURE ON HOSPITALIZATIONS AND COSTS
CAREMARK CAREPATTERNS®HEART FAILURE HOME MONITORING PROGRAM IMPROVES PARTICIPANTS' HOME MONITORING COMPLIANCE
USE OF ß-BLOCKERS FOR TREATING HEART FAILURE AMONG THE ELDERLY IN BRITISH COLUMBIA, CANADA, 1993–2001
TRENDS IN PHARMACY USE AMONG VETERANS WITH CHRONIC HEART FAILURE (1999–2002)
DECREASING HOSPITALIZATIONS FOR HEART FAILURE IN BRITISH COLUMBIA, CANADA, 1993–2001
EFFECTIVENESS OF CLINICAL PATHWAYS FOR INPATIENT HEARTH FAILURE TREATMENT
HEALTH AND ECONOMIC BURDEN OF POOR MEDICATION ADHERENCE IN THE UNITED STATES
EVALUATING THE DIAGNOSTIC VALIDITY OF ADMINISTRATIVE CLAIMS DATA FOR COMMON CHRONIC DISEASES
WHAT IS THE RELEVANCE OF AGE GROUPS IN SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS? A COST— UTILITY ANALYSIS IN MEXICO
COST EFFECTIVENESS OF ATORVASTATIN (LIPITOR) AS SINGLE THERAPY AND DUAL THERAPY WITH EZETIMIBE (ZETIA)
COST-EFFECTIVENESS OF EZETIMIBE CO-ADMINISTRATION IN CHD PATIENTS NOT AT GOAL WITH CURRENT STATIN THERAPY IN HONG KONG
AN ECONOMIC ANALYSIS OF EZETIMIBE/SIMVASTATIN COMPARED TO USUAL CARE WITH STATIN MONOTHERAPY
COST-UTILITY ANALYSIS FOR STATINS IN MEXICO
PREDICTORS OF COMPLIANCE AND PERSISTENCE TO STATIN THERAPY AMONG TEXAS MEDICAID PATIENTS
COMPLIANCE WITH STATIN TREATMENT
DOES PLAN DESIGN AFFECT THERAPY ADHERENCE FOR CHRONIC CONDITIONS?
EVALUATION OF FACTORS RELATED TO DIAGNOSIS OF HYPERLIPIDEMIA
MONITORING OF LIPID LEVELS AND ADVERSE EVENTS AMONG TEXAS MEDICAID PATIENTS ON STATIN THERAPY
EFFECT OF CO-PAYMENT ON THE INITIATION OF STATINS AFTER CORONARY HEART DISEASE HOSPITALIZATION
EFFECT OF CLINICAL PHARMACIST INTERVENTION ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) OUTCOMES IN AN AMBULATORY SETTING
CHOLESTEROL GOAL ATTAINMENT IN DYSLIPIDEMIC TREATED PATIENTS AND INCIDENCE OF CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE
PREDICTING STATIN COMPLIANCE IN NEW STARTERS WITH PHARMACY CLAIMS
A COMPARISON OF THE ELIXHAUSER AND CHARLSON INDICES TO CONTROL FOR CONFOUNDING IN HEALTH OUTCOMES STUDIES
PREVALENCE, AWARENESS AND CONTROL OF HYPERTENSION AMONG LATINOS IN LOS ANGELES COUNTY, CA, USA
PHARMACOECONOMIC EVALUATION OF ANTIHYPERTENSIVE THERAPY IN OLABISI ONABANJO UNIVERSITY TEACHING HOSPITAL, SAGAMU, OGUN SATATE, NIGERIA
PATIENT EDUCATION AND ADHERENCE AND HYPERTENSION CONTROL IN TWO ACADEMIC MEDICAL CENTER PRIMARY CARE PRACTICES
ADHERENCE TO ANTIHYPERTENSIVE MEDICATIONS RELATED TO COPAYMENT LEVEL
INSURANCE COVERAGE AND AMBULATORY CARE OF HYPERTENSION FOR THE NEAR ELDERLY
PHYSICAL INACTIVITY IS ASSOCIATED WITH INCREASED HEALTH CARE USE AND EXPENDITURES IN INDIVIDUALS WITH HYPERTENSION
ANTIHYPERTENSIVE THERAPY AFTER ALLHAT
USE OF NON-US SUPPLIED PHARMACEUTICALS IN THE TREATMENT OF HYPERTENSION IN A LATINO POPULATION IN LOS ANGELES COUNTY, CA, USA
USE OF ANTIHYPERTENSIVE MEDICATIONS AMONG VETERANS NEWLY DIAGNOSED WITH HYPERTENSION
ASSESSMENT OF THE VALIDITY OF TWO CLAIMS-BASED ALGORITHMS IN IDENTIFYING HYPERTENSIVE PATIENTS
ADVANTAGES AND LIMITATIONS OF USING A WEB-BASED SURVEY TO OBTAIN PATIENT-REPORTED OUTCOMES
VENOUS THROMBOEMBOLISM PROPHYLAXIS AND DRUG USE VALUE OF ENOXAPARIN IN HOSPITALIZED MYOCARDIAL INFARCTION PATIENTS
SHORT AND LONG-TERM COST-EFFECTIVENESS OF EARLY AND SUSTAINED DUAL ORAL ANTIPLATELET THERAPY WITH CLOPIDROGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION
A MULTI-COUNTRY HEALTH ECONOMIC EVALUATION OF N-3 POLYUNSATURATED FATTY ACIDS (PUFA) IN THE SECONDARY PREVENTION AFTER MI
COST ANALYSIS ON ANTICOAGULANT DRUG MARKET
ECONOMIC AND HUMANISTIC BURDEN OF POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE IN GERMANY
PREVALENCE OF METABOLIC SYMDROME IN KOREAN AMERICANS IN THE UNITED STATES
EVALUATION AND COMPARISON OF DIFFERENT MODELS OF METABOLIC SYNDROME USING CONFIRMATORY FACTOR ANALYSIS
COST OF MAJOR BLEEDING FOLLOWING MAJOR ORTHOPEDIC SURGERY
CLINICAL AND ECONOMIC ISSUES IN THE PREVENTION OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED ORTHOPEDIC PATIENTS
COST SAVINGS ASSOCIATED WITH FINER DOSING INCREMENTS THROUGH THE USE OF NORDITROPIN NORDIFLEX® IN THE UNITED STATES
COST-UTILITY OF NORDITROPIN® (R-DNA SOMATROPIN) IN CHILDREN WITH GROWTH HORMONE DEFICIENCY
HEALTH STATUS VALUES (UTILITIES) FOR THE SWEDISH POPULATION
GENERIC AND DISEASE—SENSITIVE INSTRUMENTS SEEM TO MEASURE QUALITY OF LIFE IN A SIMILAR WAY
ESTIMATING THE QUALITY OF LIFE DEFICIT IN ADULT GROWTH HORMONE DEFICIENCY USING AN EQ-5D CALIBRATED INDEX
EVALUATION OF THE ASSOCIATION BETWEEN HEIGHT AND HEALTH-RELATED UTILITY (EQ5DINDEX)
EFFECTIVENESS OF EPOETIN ALFA IN REDUCING THE NUMBER OF BLOOD TRANSFUSIONS IN CRITICALLY ILL SICU PATIENTS
IMPACT OF ANEMIA ON IN-HOSPITAL FALLS
DOES ANEMIA CONTRIBUTE TO LONGER LENGTH OF STAY IN PATIENTS WITH IN-HOSPITAL FALLS?
COST-EFFECTIVENESS OF TRANSFUSING BLOOD PLATELETS PREPARED WITH PATHOGEN INACTIVATION TREATMENT IN CHINA
RECOMBINANT HUMAN FACTOR VII USE
A HIDDEN EPIDEMIC AMONG ACUTE CARE INPATIENTS
COST EFFECTIVENESS OF INTERVENTIONS TO IMPROVE ADHERENCE
THE MEDINET-PROJECT—A FEASIBILITY STUDY ON MEDICATION COMPLIANCE UNDER REAL LIFE CONDITIONS
IMPACT OF INCREASED COPAYMENTS ON THE SWITCHING AND DISCONTINUATION RATES FOR NON FORMULARY MEDICATIONS
IMPACT OF COST ON MEDICATION COMPLIANCE IN PATIENTS WITH DIFFERENT LEVELS OF PERCEIVED BENEFITS
TOOLS TO INCREASE THE APPROPRIATENESS OF ALBUMIN UTILIZATION IN AN ITALIAN COMMUNITY HOSPITAL
SUMMARIZING DRUG USE OVER TIME
PRESCRIPTION DRUG NONCOMPLIANCE AMONG TRICARE BENEFICIARIES AT MILITARY PHARMACIES
EVALUATION OF A CLINICAL PHARMACOKINETIC MONITORING SYSTEM
EVALUATION OF A PLAN-PARTICIPANT MAILING PROGRAM TO ENCOURAGE USE OF MAIL-SERVICE PHARMACY AND FORMULARY DRUGS
UTILIZATION AND COSTS OF A 90-DAY RETAIL PROGRAM IN COMPARISON WITH 30-DAY RETAIL AND MAIL SERVICES
IMPACT OF A 90-DAY RETAIL PROGRAM ON PRESCRIPTION DRUG EXPENDITURES
SOCIAL AND ECONOMIC FACTORS AFFECTING INTENTIONAL PRESCRIPTION DRUG NON-COMPLIANCE AMONG NOVA SCOTIA SENIORS
TRENDS IN THE PREVALENCE OF INAPPROPRIATE PRESCRIBING AMONG ELDERLY MEDICARE BENEFICIARIES, 1992–2001
MAKING A CASE FOR EMPLOYING SOCIETAL PERSPECTIVE IN THE EVALUATION OF MEDICAID FORMULARIES
PHARMACOECONOMIC EDUCATION AT MEDICAL SCHOOLS IN TURKEY
ADVERTISING IN RESPONSE TO NEW PRODUCT ENTRY
MODELING THE COST AND UTILIZATION OF MAIL ORDER VS. COMMUNITY PHARMACY IN A MEDICAID POPULATION
THE INFLUENCE OF DRUG COPAY CHANGE ON DRUG UTILIZATION
MEDICATION NEEDS OF ELDERLY INDIVIDUALS WITHOUT PRESCRIPTION DRUG COVERAGE
EFFECT OF A PHARMACY BENEFIT CHANGE ON ACCURACY OF PRESCRIPTION DATABASE'S DAYS SUPPLY VARIABLE
TRENDS IN PHARMACEUTICAL SPENDING GROWTH IN THE UNITED STATES, 1998–2002
IMPACT OF HEALTH INSURANCE ON HEALTH-RELATED QUALITY OF LIFE
FINANCING TO MEDICINES IN MEXICO
THE DETERMINANTS OF EXPENDITURES ON PHARMACEUTICALS AND OTHER MEDICAL NON-DURABLES IN OECD COUNTRIES
ANALYSIS OF PRESCRIBING PATTERN WITH THE NEGATIVE LIST FORMULARY SYSTEM IN KOREA
THE CURRENT AND FUTURE OF PHARMACOECONOMICS IN UKRAINE
QUALITY OF ECONOMIC MODELS IN DOSSIERS SUBMITTED UNDER THE AMCP FORMAT
THE EFFECT OF CORPORATE STRUCTURE ON FORMULARY DESIGN
AN ANALYSIS OF PUBLICATION RATES OF ABSTRACTS PRESENTED AT THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH (ISPOR) INTERNATIONAL AND EUROPEAN CONFERENCES DURING YEARS 2000 THROUGH 2003
USE OF EMERGENCY DEPARTMENTS BY HOMELESS PERSONS FOR NON-EMERGENCY CARE DURING ONE YEAR
SAFETY NET ACTIVITIES STRUCTURAL CHARACTERISTICS & MEMBERSHIP IN LOCAL HOSPITAL SYSTEMS
TRENDS AND OUTCOMES ASSOCIATE WITH DTCA PRINT SUMMARY FORMATS
UTILITY OF MEDIA ON HEALTH PROMOTION AND SELFMEDICATION
AN ASSESSMENT OF THE ASSOCIATION BETWEEN UNDERLYING WORKER MEDICAL CONDITIONS AND WORKER ABSENTEEISM IN THE US
OUTCOMES OF TECHNOLOGY APPLICATION ON PHARMACISTS JOB PERFORMANCE
EXAMINING THE QUALITY OF HEALTH ECONOMIC ANALYSES SUBMITTED TO THE PHARMACEUTICAL BENEFITS BOARD IN SWEDEN.—DATA FROM THE FIRST TWO YEARS
EVALUATING PHARMACEUTICALS FOR REIMBURSEMENT IN KOREA
A CENTRAL COMPUTERIZED DRUG PRIOR-AUTHORIZATION PROCESS IN A MANAGED CARE SETTING IN ISRAEL
DEVELOPMENT AND VALIDATION OF A CLAIMS-BASED RISK ASSESSMENT MODEL TO PREDICT PHARMACY EXPENDITURES IN A COMMERCIAL POPULATION
DEVELOPING KEY PERFORMANCE INDICATORS FOR THE AUSTRALIAN REIMBURSEMENT SYSTEM
A PRELIMINARY ANALYSIS OF THE RELATIONSHIP BETWEEN CONSULTATION LENGTH AND PRESCRIBER ACTIVITY IN UK GENERAL PRACTICE
AN EXPLORATION OF PATIENT FACTORS INFLUENCING PRESCRIBER ACTIVITY IN UK GENERAL PRACTICE
FACTORS THAT INFLUENCE PRESCRIBING OF LOW- MOLECULAR-WEIGHT HEPARINS
USING THE TRANSTHEORETICAL MODEL (TTM) TO EXPLAIN, PREDICT OR INFLUENCE PHYSICIAN PATIENT CARE BEHAVIOR
EVALUATING THE EFFECTIVENESS OF A PROTOCOL FOR SEDATION OF MECHANICALLY VENTILATED PATIENTS IN AN ACUTE CARE SETTING
IMPACT OF PRESCRIBING GUIDELINES FOR INPATIENT ANTICOAGULATION
COST-MINIMIZATION ANALYSIS OF SEROLOGIC SCREENING POLICY OPTIONS FOR US ARMY ACCESSION IMMUNIZATIONS
ISPOR PHARMACOECONOMICS & OUTCOMES RESEARCH ABSTRACTS
BRIEF SUMMARY FORMATS OF DTCA TO IMPROVE CONSUMER COMPREHENSION
INCORPORATING OF HERD IMMUNITY INTO PHARMACOECONOMIC EVALUATION OF PNEUMOCOCCAL CONJUGATE VACCINE PNC-7
THE COST-EFFECTIVENESS OF EXPANDING NEWBORN SCREENING FOR INHERITED METABOLIC DISORDERS USING TANDEM MASS SPECTROMETRY
DIRECT COST OF TREATMENT FOR AUTISM SPECTRUM DISORDER IN CALIFORNIA MEDICAID
THE QUALITY OF COMMUNITY PEDIATRICIAN'S PRESCRIPTIONS
USE OF ANTIBIOTICS IN ASSOCIATION WITH DIAGNOSES OF UPPER RESPIRATORY INFECTIONS IN A LARGE ISRAELI HMO
TESTING FOR STREPTOCOCCAL INFECTIONS IN CHILDREN WITH PHARYNGITIS TREATED WITH ANTIBIOTICS IN A LARGE ISRAELI HMO, 2003
THE PREVALENCE OF POTENTIALLY INAPPROPRIATE MEDICATION USE IN THE ELDERLY
INAPPROPRIATE PRESCRIBING FOR ELDERLY PATIENTS IN TWO OUTPATIENT SETTINGS
MORAL HAZARD AND PRESCRIPTION DRUG USE AMONG NON-INSTITUTIONALIZED ELDERLY MEDICARE BENEFICIARIES
AN EXAMINATION OF SELF-REPORTED CHRONIC CONDITIONS AND HEALTH STATUS IN THE 2001 MEDICARE HEALTH OUTCOMES SURVEY
THE EFFECT OF OVER-THE-COUNTER DRUG MISUSE AND THE ASSOCIATED ADES ON HRQOL IN THE ELDERLY
RELATIONSHIP BETWEEN QUALITY OF LIFE AND INAPPROPRIATE DRUG USE
COST-EFFECTIVENESS ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) TREATMENTS
USE OF SILDENAFIL CITRATE IN NON-ADHERENT PATIENTS WITH CVD, DIABETES OR DEPRESSION
IMPACT OF BENEFIT DESIGN ON PDE-5 UTILIZATION AND COSTS IN A LARGE PBM DATABASE
UTILIZATION PATTERNS OF SIDENAFIL CITRATE IN A SENIOR MANAGED CARE POPULATION
EVALUATION OF TADALAFIL AND VARDENAFIL TREATMENT PATTERNS IN PRIOR SILDENAFIL USERS
DIRECT COSTS OF ERECTILE DYSFUNCTION IN A MANAGED CARE SETTING–EVIDENCE FROM A LARGE NATIONAL CLAIMS DATABASE
COST-EFFECTIVENESS OF PHARMACIST PRESCRIBING AUTHORITY FOR EMERGENCY CONTRACEPTION IN BRITISH COLUMBIA
COST OF ILLNESS STUDY OF NAUSEA AND VOMITING OF PREGNANCY IN CANADA
ADJUSTMENT FOR PUBLICATION BIAS CHANGES THE APPARENT EFFICACY OF HORMONE TREATMENT- UNADJUSTED DATA MIGHT DISTORT THE RISK–BENEFIT TRADE OFF
NEW INSIGHTS INTO THE PLACEBO EFFECTS
HEALTH PREFERENCES AND WILLINGNESS TO PAY TO REDUCE EXPOSURE TO POST-MENOPAUSAL RISK FACTORS
OUTPATIENT COMMUNITY-ACQUIRED PNEUMONIA IN NON-ELDERLY ADULTS
EFFECT OF INAPPROPRIATE ANTIBIOTIC THERAPY ON CLINICAL OUTCOMES OF PATIENTS WITH PSEUDOMONAS AERUGINOSA BACTEREMIA
DURATION OF ANTIBIOTIC TREATMENT IN HOSPITALIZED PATIENTS WITH COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS (CSSSI)
IMPACT OF EMPIRIC ANTIFUNGAL THERAPY ON MORTALITY IN HOSPITALIZED PATIENTS WITH BLOODSTREAM CANDIDEMIA
COST ANALYSIS OF A FEBRILE NEUTROPENIA ALGORITHM WITH RESPECT TO EMPIRICAL ANTIFUNGAL THERAPY IN ADULT HEMATOLOGY/ONCOLOGY PATIENTS
ECONOMIC EVALUATION OF VACCINATION AGAINST STREPTOCOCCUS PNEUMONIAE IN GERMANY INCLUDING HERD IMMUNITY EFFECTS
AN UPDATED EVALUATION OF THE COST-EFFECTIVENESS OF VACCINATING ADOLESCENTS FOR PERTUSSIS
ECONOMIC EVALUATION OF INTRAVENOUS ITRACONAZOLE IN PRESUMED SYSTEMIC FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS IN KOREA
EXPLORING THE COST-EFFECTIVENESS OF AN IMMUNISATION PROGRAMME FOR ROTAVIRUS GASTROENTERITIS IN THE UNITED KINGDOM
ECONOMIC ANALYSIS OF VACCINATION WITH MENACTRA IN THE US
A COST—EFFECTIVENESS ANALYSIS MODEL FOR TREATMENT OF CANDIDIASIS AND INVASIVE ASPERGILLOSIS IN MEXICO
INFANTILE GASTROENTERITIS IN THE COMMUNITY
ANNUAL COST FOR THE TREATMENT OF PATIENTS HOSPITALIZED WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN THE UNITED STATES
OUTPATIENT COMMUNITY-ACQUIRED PNEUMONIA IN NON-ELDERLY ADULTS
IMPACT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS ON INPATIENT COSTS FOR AN ACADEMIC MEDICAL CENTER
COST-UTILITY OF CHRONIC HEPATITIS ‘C’ TREATMENT WITH THYMOSIN ALPHA 1 IN MEXICO
A COMPARISON OF METHODS TO ASSESS QUALITY OF LIFE IN ECONOMIC ANALYSES OF HEPATITIS C TREATMENTS
ESTIMATES OF HEALTH CARE COSTS FOR LAMIVUDINE- REFRACTORY CHRONIC HEPATITIS B (CHB) PATIENTS
UTILISATION OF ANTIBIOTICS WITHIN THE SLOVAK REPUBLIC
IMPROVEMENT IN ANTIMALARIAL DRUGS ACCESS
AWARENESS AND KNOWLEDGE OF HPV AMONG UNIVSERSITY STUDENTS ATTENDING AN HBCU
HOSPITALIZED COMMUNITY ACQUIRED PNEUMONIA
ARE SUBJECTS ENROLLED IN CANDIDEMIA CLINICAL TRIALS REPRESENTATIVE OF MOST HOSPITALIZED PATIENTS WITH THIS DISORDER
ACUTE SINUSITIS OUTCOMES AND CHARGES
CHRONIC RHINOSINUSITIS TREATMENT
VALIDATION OF A HEALTH-RELATED QUALITY OF LIFE INSTRUMENT FOR HEPATITIS B PATIENTS IN SINGAPORE
PROSPECTIVE OBSERVATIONAL STUDY OF PATIENT REPORTED OUTCOMES FOR AZITHROMYCIN VS. USUAL CARE IN THE TREATMENT OF ACUTE BACTERIAL EXACERBATIONS OF CHRONIC BRONCHITIS
THE COST-EFFECTIVENESS OF PREVENTING MOTHER-TO- CHILD TRANSMISSION OF HIV IN CHINA
COST OF THERAPY FOR ARV NAIVE HIV-INFECTED PATIENTS
ANEMIA IN HIV/AIDS PATIENTS IN THE HAART ERA
USE OF THE SYMPTOMS DISTRESS MODULE IN AN INTERNATIONAL STUDY
ASSESSMENT OF COMORBIDITY AND INCIDENCE RATE OF ALZHEIMER'S DISEASE IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM
THE COST-EFFECTIVENESS OF DONEPEZIL AND RIVASTIGMINE IN THE TREATMENT OF ALZHEIMER'S DISEASE IN THAILAND PRIVATE HOSPITAL
THE COST-EFFECTIVENESS OF QUETIAPINE FOR ALZHEIMER'S DISEASE IN COMMUNITY DWELLING PATIENTS
NURSING HOME RESIDENTS WITH ALZHEIMER'S DISEASE
DRUG PERSISTENCY OF TWO CHOLINESTERASE INHIBITORS—RIVASTIGMINE VERSUS DONEPEZIL AMONG ELDERLY PATIENTS WITH ALZHEIMER'S DISEASE
OUTCOMES OF ANTIDEPRESSANT USE IN PATIENTS WITH ALZHEIMER'S DISEASE IN THE CALIFORNIA MEDICAID PROGRAM
DIAGNOSING PHYSICIANS, PRESCRIPTION CHOICE AND PATTERNS FOR ALZHEIMER'S DISEASE IN CALIFORNIA MEDICAID PROGRAM
USING A TOUCHTONE TELEPHONE TO COLLECT DATA FROM ELDERLY CAREGIVERS OF PATIENTS WITH ALZHEIMER'S DISEASE
CARE COSTS OF PARTIAL REFRACTORY EPILEPSY IN MEXICO
PSYCHOMETRIC EVALUATION OF EPILEPSY-SPECIFIC QUALITY OF LIFE INSTRUMENTS
AN ECONOMIC EVALUATION OF TRIPTAN PRODUCTS FOR MIGRAINE
TRIPTANS FOR MIGRAINE THERAPY
COST-EFFECTIVENESS OF ELETRIPTAN VERSUS ZOLMITRIPTAN
IMPACT OF MIGRAINE FREQUENCY ON HEALTH UTILITIES
FURTHER VALIDATION OF THE MIGRAINE TREATMENT SATISFACTION MEASURE
DEVELOPMENT OF A UNIQUE INTERNET & PHONE BASED SYSTEM TO CAPTURE MIGRAINE TREATMENT OUTCOMES
EFFECT OF IMMUNOMODULATORY THERAPY AND OTHER FACTORS ON PRODUCTIVITY IN MS
THE IMPACT OF MEDICARE PART D ON ECONOMIC BARRIERS TO PRESCRIPTION MEDICATIONS AMONG BENEFICIARIES WITH MULTIPLE SCLEROSIS
DEVELOPMENT OF THE MULTIPLE SCLEROSIS TREATMENT SATISFACTION QUESTIONNAIRE (MSTCQ)
RESTLESS LEGS SYNDROME PLACES A SUBSTANTIAL BURDEN ON THE HEALTH-RELATED QUALITY OF LIFE OF US AND EUROPEAN PATIENTS
FUNCTIONAL LIMITATIONS, MENTAL HEALTH, AND RESOURCE USE ASSOCIATED WITH THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH RESTLESS LEGS SYNDROME
COST-EFFECTIVENESS OF PRAMIPEXOLE COMPARED WITH PIRIBEDIL IN EARLY PARKINSON'S DISEASE PATIENTS
COST-UTILITY ANALYSIS FOR EARLY PATIENTS WITH PARKINSON'S DISEASE TREATED BY DOPAMINE AGONISTS
PATTERNS OF RESOURCE USE IN PATIENTS WITH DIFFERENT SEVERITIES OF PARKINSON'S DISEASE
COST AND USE OF PARKINSONISM-INDUCING DRUGS AMONG MEDICARE BENEFICIARIES
TREATMENT SATISFACTION AND PRINCIPAL CAUSES OF TERMINATION OF DRUG TREATMENT OF PARKINSON'S DISEASE IN RUSSIA
PREVALENCE OF INSOMNIA AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A LARGE DATABASE
THE PREVALENCE OF INSOMNIA IN PATIENTS WITH DRUG DEPENDENCY OR ABUSE
COST-EFFECTIVENESS OF LONGER-TERM TREATMENT WITH ESZOPICLONE 3MG IN ADULTS WITH PRIMARY INSOMNIA
FORECASTING THE IMPACT OF ADDING A NEW DRUG ON FORMULARY USING MEDICAL CLAIMS DATA AND CLINICAL LITERATURE
CLINICAL PRIOR AUTHORIZATION PROGRAM
PHYSICIAN AND PATIENT DETERMINANTS OF THE TREATMENT OF SLEEP DIFFICULTIES IN OUTPATIENT SETTINGS IN THE UNITED STATES
SLEEP COMPLAINTS AND DIAGNOSES IN THE NATIONAL AMBULATORY MEDICAL CARE SURVEY
SEDATIVE HYPNOTICS EMPLOYED TO TREAT PATIENTS WITH AND WITHOUT INSOMNIA COMPLAINTS IN THE NATIONAL AMBULATORY MEDICAL CARE SURVEY
USING PATIENT REPORTED OUTCOMES (PROS) TO DETERMINE THE PREVALENCE OF INSOMNIA IN FOUR COUNTRIES
PULMONOLOGISTS' PERCEPTIONS OF ANEMIA IN COPD
AN ASSESSMENT OF DIAGNOSIS AND TREATMENT OF COPD IN PRIMARY CARE VIA AN ELECTRONIC MEDICAL RECORD DATABASE
ACUTE EXACERBATION OF CHRONIC BRONCHITIS (AECB) TREATMENT EFFECTIVENESS
ESTIMATING THE NUMBER OF CASES OF DIAGNOSED CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
EVALUATION OF THE ASSOCIATION BETWEEN SEVERITY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) WITH HEALTH-RELATED UTILITY (EQ5DINDEX) AND HEALTH CARE RESOURCE USE
COMPARISON OF RESOURCE USE AND DIRECT COSTS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH AND WITHOUT COMORBID DEPRESSION IN 2001
PHARMACOECONOMIC ANALYSIS OF TIOTROPIUM THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASES IN HONG KONG ¡V A PRELIMINARY REPORT
COST-EFFECTIVENESS ANALYSIS OF TIOTROPIUM FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS IN JAPAN
ADHERENCE TO RESPIRATORY MEDICATIONS IN VA PATIENTS WITH CHRONIC LUNG DISEASE
PREDICTORS OF DRUG PERSISTENCY FOR ASTHMA AND COPD PATIENTS
COMMUNITY PHARMACISTS AND TUBERCULOSIS IN THE DOTS ERA- A CROSS-SECTIONAL STUDY OF LAGOS STATE OF NIGERIA
RACIAL DISPARITIES IN PREDICTORS OF HEART FAILURE IN MEDICAID PATIENTS WITH COPD
HEALTH CARE EXPENDITURE AND UTILIZATION FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
RISK-BENEFIT ASSESSMENT OF TELITHROMYCIN FOR THE TREATMENT OF CAP USING QUALITY-ADJUSTED DAYS (QAD) LOST
PREDICTING EXACERBATION EVENTS IN COPD USING ADMINISTRATIVE DATA
COST-EFFECTIVENESS ANALYSIS OF AMEVIVE™ (ALEFACEPT) IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
NUMBERS-NEEDED-TO-TREAT AND ASSOCIATED COSTS OF CARE FOR TREATMENT OF MODERATE-TO-SEVERE PSORIASIS
FACTORS ASSOCIATED WITH MEDICATION USE AFFECTING HEALTH CARE COSTS IN PATIENTS WITH PSORIASIS IN THE UNITED STATES
THE LIFETIME COST OF TREATING SEVERE PSORIASIS WITH HOME UVB THERAPY
COST-UTILITY ANALYSIS OF AMEVIVE™ (ALEFACEPT) IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
INTERPRETING SCORES ON THE QUALITY OF LIFE INDEX FOR ATOPIC DERMATITIS (QOLIAD)
USING DUAN'S SMEARING ESTIMATOR TO MEASURE COST OF CHRONIC HAND DERMATITIS (CHHD) IN A MASSACHUSETTS HEALTH MAINTENANCE ORGANIZATION (HMO)
IMPACT OF ATOPIC DERMATITIS ON THE QUALITY-OF-LIFE OF PARENTS OF CHILDREN WITH ATOPIC DERMATITIS
PREVALENCE OF CHRONIC HAND DERMATITIS AND ITS IMPACT ON PATIENT–REPORTED OUTCOMES IN A MANAGED CARE POPULATION
THE NEGATIVE IMPACT OF PSORIASIS ON WORK PRODUCTIVITY
DEVELOPING MARKOV-MODEL INCLUDING TOBACCO- ASSOCIATED DISEASES TO EVALUATE SMOKING CESSATION THERAPY IN JAPAN
CONFIRMATORY FACTOR ANALYSIS AND RELIABILITY OF THE “SMOKING EFFECTS INVENTORY”
CONFIRMATORY VALIDATION OF THE BRIEF QUESTIONNAIRE OF SMOKING URGES
COST-EFFECTIVENESS OF CLOPIDOGREL VERSUS ASPIRIN IN THE PREVENTION OF ISCHEMIC EVENTS IN STROKE AND TIA PATIENTS
EVALUATING THE POTENTIAL COST-EFFECTIVENESS OF FUTURE ANTICOAGULANT DRUGS VS. WARFARIN IN THE PREVENTION OF STROKE AND MAJOR BLEEDS IN ATRIAL FIBRILLATION PATIENTS
THE EVALUATION OF HEALTH RELATED UTILITY (EQ5DINDEX) AND RESOURCE USE IN PATIENTS WITH STROKE COMPLICATED BY UPPER AND LOWER LIMB SPASTICITY
FREQUENCY OF INR TESTING IN MEDICARE BENEFICIARIES AT HIGH RISK FOR STROKE
CONTINUITY OF CARE IN STROKE PATIENTS UNDER REHABILITATION IN MEXICO
STROKE RECURRENCE AND PERSISTENCE ON DRUG THERAPY IN A MEDICAID POPULATION
DISABILITY MEASURES IN STROKE
BUILDING A LINK BETWEEN DISABILITY AFTER AN ISCHEMIC STROKE AND NEED FOR FOLLOW-UP CARE
ECONOMIC EVALUATION OF SIROLIMUS-ELUTING STENTS IN JAPAN
INPATIENT RESOURCE UTILIZATION AND COSTS OF PROCEDURES IMPLANTING DRUG-ELUTING STENTS IN COMPLEX CASES
COST-UTILITY OF STENTING FOR SYMPTOMATIC INTRACRANIAL ATHEROSCLEROTIC DISEASE
DRUG-ELUTING VERSUS BARE-METAL CORONARY STENTS
ECONOMIC BURDEN OF ILLNESS ASSOCIATED WITH CODED POSTOPERATIVE ILEUS AFTER OPEN LAPAROTOMIES
ELECTIVE SURGERIES IN THE US
THE IMPACT OF THE RX-TO-OTC SWITCH OF LORATADINE AND CHANGES IN PRESCRIPTION DRUG BENEFITS ON UTILIZATION AND COST OF THERAPY
PATIENT PERCEPTIONS REGARDING THE USE OF OVER- THE-COUNTER CLARITIN
WILLINGNESS TO PAY FOR INTRANASAL CORTICOSTEROID THERAPY
COX-2 USE IN THE POST-ROFECOXIB ERA
THE IMPACT OF SPECIALTY CARE ON THE UTILIZATION OF NEW DRUGS
TESTING THE BMJ CHECKLIST AS A QUALITY ASSESSMENT TOOL FOR ECONOMIC EVALUATIONS
A REVIEW OF TOTAL COST BURDEN OF FIBROMYALGIA
DEVELOPMENT OF BENCHMARK METHODOLOGY TO IDENTIFY GOUT PATIENTS AND GOUT ATTACKS FROM A RETROSPECTIVE DATABASE ANALYSIS
HEALTH CARE UTILIZATION AND DIRECT MEDICAL COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN AN DEVELOPING COUNTRY
SURVEY OF CURRENT TREATMENT PRACTICES OF RHEUMATOLOGISTS IN PRESCRIBING TUMOR NECROSIS FACTOR INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS
ALTERNATIVE DECISION ANALYSIS MODELING IN THE ECONOMIC EVALUATION OF TUMOR NECROSIS FACTOR INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS
EFFECTS OF ADALIMUMAB MONOTHERAPY ON HEALTH UTILITY AND FATIGUE IN PATIENTS WITH LONG-STANDING, SEVERE RHEUMATOID ARTHRITIS (RA)
SATISFACTION WITH PAIN MEDICATION AND INTENTION TO COMPLY WITH TREATMENT
THE IMPACT OF DEPRESSION ON RHEUMATOID ARTHRITIS PATIENT QUALITY OF LIFE
ABATACEPT (CTLA4IG) IN COMBINATION WITH METHOTREXATE DEMONSTRATES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES OVER TWO YEARS IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE
META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF SCREENING TESTS FOR COLORECTAL CANCER
SURVIVAL ANALYSIS OF PAIN RELIEF PROVIDED BY DOXEPIN ORAL RINSE FOR ORAL MUCOSITIS PATIENTS
TIME TO CANCER DIAGNOSIS (TDX) IN YOUNG AMERICANS DEPENDS ON TYPE OF CANCER AND HEALTH INSURANCE STATUS
ECONOMIC EVALUATION OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. OTHER IV BISPHOSPHONATES IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES
BUDGET IMPACT ANALYSIS OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. ORAL IBANDRONATE OR IV GENERIC PAMIDRONATE IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES
ECONOMICS OF PRIMARY & SECONDARY BREAST CANCER PREVENTIVE STRATEGIES
THE COST-EFFECTIVENESS OF CAPECITABINE AS ADJUVANT ORAL CHEMOTHERAPY FOR DUKE'S C COLON CANCER
THE COST-EFFECTIVENESS OF PROSTATE-SPECIFIC ANTIGEN SCREENING FOR PROSTATE CANCER DETECTION
THE COST-EFFECTIVENESS OF HERCEPTIN® IN ADJUVANT SETTING
ECONOMIC IMPACT OF PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME IN PATIENTS WITH HORMONE- REFRACTORY PROSTATE CANCER
THE COST OF CANCER IN KOREA
ESTIMATING COSTS OF UNCONTROLLED CHEMOTHERAPY- INDUCED NAUSEA AND VOMITING AMONG WORKING-AGE CANCER PATIENTS
SURVIVAL AND COST FOLLOWING BREAST CANCER RECURRENCE
IS COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE COST-EFFECTIVE COMPARED WITH COMBINED ANDROGEN BLOCKADE WITH FLUTAMIDE?
RESOURCE UTILIZATION AMONG PROSTATE CANCER PATIENTS WITH BONE PAIN
THE CLINICAL OUTCOMES AND COSTS OF TREATING ONCOLOGY PATIENTS FOR SEVERE SEPSIS
ASSESSMENT OF BREAST CANCER KNOWLEDGE, SCREENING BEHAVIOR, RISK PERCEPTIONS, AND WILLINGNESS TO CONSUME CHEMOPREVENTIVE AGENT IN WOMEN IN THE WEST VIRGINIA MEDICAID PROGRAM (WVMP)
OPIOID USE IN A LARGE NATIONAL HOSPICE POPULATION
VARIATIONS IN INPATIENT PROSTATE CANCER TREATMENT IN FLORIDA
A SYSTEMATIC REVIEW OF PHYSICIAN KNOWLEDGE AND PRACTICE PATTERNS REGARDING COLORECTAL CANCER SCREENING
RETRANSFORMATION OF ESTIMATED LOG-TRANSFORMED COSTS WHEN THE ERRORS PRESENT HETEROSKEDASTICITY
ESTIMATION OF CENSORED MEDICAL COUNT DATA
RELIABILITY OF SPANISH-LANGUAGE HUI MEASUREMENTS IN SURVIVORS OF CANCER IN CHILDHOOD
HANDLING MISSING PATIENT REPORTED OUTCOMES (PRO) DATA FOR PREMATURE WITHDRAWALS FROM CLINICAL TRIALS OF SEVERE DISEASES
RELIABILITY AND VALIDITY OF BRAZILIAN PORTUGUESE HEALTH UTILITIES INDEX (HUI) QUESTIONNAIRES FOR ASSESSING THE HEALTH STATUS OF SURVIVORS OF CHILDHOOD CANCER
DERIVING A PREFERENCE-BASED INDEX FROM THE MD ANDERSON SYMPTOM INVENTORY IN CANCER PATIENTS
INCONGRUENT DEFINITIONS OF RISK AND UNCERTAINTY AMONG CLINICAL ONCOLOGISTS AND ITS IMPLICATIONS FOR DECISION MAKING
PREVALENCE OF CO-MORBID CONDITIONS AND CONCOMITANT MEDICATION USE AMONG TYPE-2 DIABETES PATIENTS IN A STATE MEDICAID POPULATION
IMPACT OF DEPRESSION ON INCIDENCE OF TYPE-2 DIABETES IN A STATE MEDICAID POPULATION
EARLY DETECTION OF CVD BY MYOCARDIAL PERFUSION IMAGING IN ASYMPTOMATIC PATIENTS WITH DIABETES
GLYCEMIC RESPONSE TO PIOGLITAZONE THERAPY IN AFRICAN-AMERICAN AND LATINO PATIENTS WITH TYPE-2 DIABETES
CAN USE OF GLITAZONES REDUCE THE RISK OF ALZHEIMER'S DISEASE IN PATIENTS WITH DIABETES?
TREATMENT PATTERNS IN MANAGEMENT OF TYPE-2 DIABETES WITH CONCURRING COMORBIDITIES
CLINICAL JUDGMENT OF DRUG THERAPY FOR TYPE-2 DIABETES PATIENTS AND RESULTS OF HBA1C TESTS
PREVALENCE OF DIABETES MELLITUS AND TREATMENT PATTERNS BASED ON CLASSIFICATION OF BODY MASS INDEX AMONG ADULTS
FACTORS ASSOCIATED WITH A LOWER GLYCOSYLATED HEMOGLOBIN A1C (A1C) IN A DIABETIC LATINO POPULATION
ECONOMIC BURDEN OF DIABETIC RETINOPATHY IN FLORIDA
EVALUATION OF THE CLINICAL OUTCOME AND FINANCIAL COSTS OF DELAYING THE ONSET OF FRANK TYPE-2 DIABETES
EFFECT OF GLYCEMIC CONTROL ON HEALTH CARE COSTS
COST OF DIABETES COMPLICATIONS IN FRANCE, GERMANY, ITALY AND SPAIN
ECONOMIC EVALUATION OF DETEMIR-BASED BASAL/BOLUS THERAPY VERSUS NEUTRAL PROTAMINE HAGEDORN-BASED BASAL/BOLUS THERAPY FOR TYPE-1 DIABETES IN A DUTCH SETTING
DIABETIC RETINOPATHY MODELING
THE ASSOCIATION BETWEEN DIABETES RELATED MEDICAL COSTS AND GLYCEMIC CONTROL
BURDEN OF ILLNESS ASSOCIATED WITH SYMPTOMS OF DIABETIC PERIPHERAL NEUROPATHY AND DIABETIC RETINOPATHY
ECONOMIC EVALUATION OF DRUG THERAPY AMONG DIABETES MILLITUS PATIENTS IN OLABISI ONABANJO UNIVERSITY TEACHING HOSPITAL, SAGAMU, OGUN STATE, NIGERIA
COLLECTION OF COST DATA FOR DIABETES COMPLICATIONS IN CANADA AND AUSTRALIA
COMPARISON OF THE COST TO REACH A1C TARGETS IN PATIENTS WITH TYPE-2 DIABETES MELLITUS ON ORAL ANTIDIABETIC AGENTS AND EITHER BIPHASIC INSULIN ASPART 70/30 OR INSULIN GLARGINE
HEALTH CARE RESOURCE UTILIZATION AND COST IN TYPE-2 DIABETES PATIENTS RECEIVING COMBINATION SULFONYLUREA (SU) AND ROSIGLITAZONE (RSG)
LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART VERSUS SOLUBLE HUMAN INSULIN IN PATIENTS WITH TYPE 1 DIABETES IN THE UNITED KINGDOM
EVALUATION OF THE IMPACT ON THE EQ5DINDEX (HEATH- RELATED UTILITY) OF CONVERSION TO INSULIN GLARGINE (LANTUS) FOLLOWING FAILURE ON ORAL AGENTS IN PEOPLE WITH TYPE-2 DIABETES
ECONOMIC IMPACT OF CARDIOVASCULAR CO-MORBIDITY IN PATIENTS WITH TYPE-2 DIABETES
DEPRESSION IN PATIENTS WITH TYPE-2 DIABETES
BURDEN OF NON-ADHERENCE TO ORAL ANTIDIABETICS
IMPACT OF A DIABETES CARE PROJECT ON MEDICATION UTILIZATION AND ADHERENCE
AN EVALUATION OF A DISEASE MANAGEMENT PROGRAM FOR ADULT DIABETICS IN A MEDICAID POPULATION
THE EFFECT OF INSULIN TREATMENT ON HEALTH CARE UTILIZATION IN TYPE-II DIABETES
TREATMENT PATTERNS AMONG PATIENTS WITH DIABETES ON METFORMIN AND SULFONYLUREA COMBINATION THERAPY
FACTORS ASSOCIATED WITH HEALTH CARE COST SAVING IN PATIENTS WITH DIABETES TO THE CALIFORNIA MEDICAID POPULATIONS (MEDI-CAL)
THE RELATIONSHIP BETWEEN PATIENT'S TYPE OF PAYMENT AND PRESCRIPTION DRUG COSTS FOR DIABETIC PATIENTS
PRESCRIBING TRENDS FOR COMBINATION PRODUCTS IN THE TREATMENT OF TYPE-II DIABETES
NEEDLESTICK INJURY IN NURSES CARING FOR PATIENTS WITH DIABETES
FACTOR ANALYSIS AND PRELIMINARY VALIDATION OF INSULIN DELIVERY SYSTEM QUESTIONNAIRE
RELIABILITY AND VALIDITY OF THE GENERAL DIABETES KNOWLEDGE TEST
HEALTH ECONOMIC COMPARISON OF INSULIN ASPART, A FAST-ACTING INSULIN ANALOG, VERSUS HUMAN INSULIN AS MEALTIME INSULIN IN THE TREATMENT OF TYPE-1 DIABETES IN AUSTRIAN, DANISH, DUTCH, FINNISH, FRENCH, GERMAN, NORWEGIAN, SPANISH AND SWEDISH SETTINGS
MEASURING THE EFFECT OF THE VARIABILITY OF INSULIN USE ON HEALTH CARE COSTS IN DIABETES
DEVELOPMENT OF AN INTEGRATED DIABETES DATABASE ACROSS COMMUNITY CLINICS AND HOSPITALS
THE USE OF DIABETES PREVENTION PROGRAM RESULTS TO MODEL COST-EFFECTIVENESS OF THE INTERVENTION IN A MORE GENERALIZED HYPOTHETICAL POPULATION
VALIDATION OF THE GERMAN TRANSLATION OF THE NORFOLK QOL-DN, NERVE FIBER SPECIFIC QUESTIONNAIRE IN A NATIONAL, MULTICENTER COST OF ILLNESS STUDY (DIMICO) FOR DIABETIC MICROVASCULAR COMPLICATIONS IN GERMANY
ESTIMATING THE EFFECT OF SYMPTOMS OF DIABETIC PERIPHERAL NEUROPATHY AND DIABETIC RETINOPATHY ON QUALITY-OF-LIFE USING DATA FROM THE 2001–2002 NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY
ASSOCIATIONS AMONG VISUAL IMPAIRMENT, STAGE OF DIABETIC RETINOPATHY AND QUALITY OF LIFE (EQ-5D)
IS DIABETES KNOWLEDGE ASSOCIATED WITH HEALTH- RELATED QUALITY OF LIFE AMONG ENGLISH-SPEAKING SUBJECTS WITH DIABETES IN SINGAPORE?
QUALITY OF LIFE (SF12), CLINICAL OUTCOMES, AND COMORBID CONDITIONS IN PATIENTS WITH TYPE-2 DIABETES
WILLINGNESS-TO-PAY FOR INHALED INSULIN—A CANADIAN PERSPECTIVE
EVALUATION OF AN OTITIS MEDIA EDUCATION INTERVENTION IN AN INTEGRATED DELIVERY SYSTEM
PROCESS EVALUATION OF THE IMPLEMENTATION OF OTITIS MEDIA GUIDELINES IN AN INTEGRATED DELIVERY SYSTEM
COMORBIDITIES AND INCIDENCE RATE OF GLAUCOMA IN THE CALIFORNIA MEDICAID POPULATION—A CASE-CONTROL STUDY
CHARACTERIZATION OF THE FREQUENCY AND REASONS FOR CHANGES IN PHARMACOTHERAPY IN THE TREATMENT OF PRIMARY OPEN-ANGLE GLAUCOMA, NORMAL TENSION GLAUCOMA, AND OCULAR HYPERTENSION USING RETROSPECTIVE ANALYSIS OF THE GLASGOW ROYAL INFIRMARY GLAUCOMA DATABASE
REFILL COSTS AND BUDGET IMPACT OF GLAUCOMA LIPID THERAPY
A COST-BENEFIT ANALYSIS OF AN APODIZED DIFFRACTIVE MULTIFOCAL INTRA-OCULAR LENS BASED ON WILLINGNESS-TO-PAY IN CATARACT PATIENTS
THE COST-EFFECTIVENESS OF DIFFERENT CASE-FINDING STRATEGIES FOR DETECTION AND TREATMENT OF OCULAR HYPERTENSION AND PRIMARY OPEN-ANGLE GLAUCOMA BY THE OPHTHALMOLOGIST
MEDICAL CARE COSTS OF PRIMARY OPEN-ANGLE GLAUCOMA IN THE UNITED STATES
COST OF GLAUCOMA TO THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM BETWEEN 1995 AND 2002
PATIENT-REPORTED VISUAL FUNCTION IN LOW-VISION POPULATIONS (NEI-VFQ)
PREVALENCE AND RISK FACTORS FOR DIARRHEA AT A LARGE TERTIARY CARE MEDICAL CENTER
THE BUDGET IMPACT OF TEGASEROD ON A MANAGED CARE ORGANIZATION FORMULARY
THE ECONOMIC IMPLICATIONS OF SOMATROPIN [RDNA ORIGIN] MANAGEMENT IN PATIENTS WITH SHORT BOWEL SYNDROME
THE COST-EFFECTIVENESS OF TWO STRATEGIES FOR VACCINATING PATIENTS WITH HEPATITIS C VIRUS INFECTION AGAINST HEPATITIS A AND HEPATITIS B
COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) COMPARED TO LAMIVUDINE FOR THE TREATMENT OF E ANTIGEN NEGATIVE CHRONIC HEPATITIS B IN THE UK
UTILIZATION, RE-TREATMENT, AND COST OF DIFFERING LENGTHS OF H. PYLORI TREATMENT REGIMENS FROM US HEALTH CARE CLAIMS DATABASES
MANAGING CROHN'S DISEASE
EVALUATION OF OTC PRILOSEC STEP CARE PROGRAMS ON THE UTILIZATION AND COSTS OF PROTON PUMP INHIBITORS
MODELING RISK OF GI EVENTS AMONG MEDICAID NSAID USERS, USING PROPENSITY SCORES
IS THE INTRODUCTION OF REFERENCE BASED PRICING FOR PATENT PROTECTED DRUGS A COST-SAVING OPTION FOR HEALTH CARE?
LINKING SYMPTOMS SEVERITY AND DIURNALITY TO PRODUCTIVITY LOSS—A NEW CONCEPTUAL APPROACH
COMPARISON OF THE MEDICATION POSSESSION RATIO ALONE AND IN COMBINATION WITH BREAKTHROUGH EVENTS FOR CLASSIFYING PATIENTS WITH ACID RELATED DISEASES
USING ADVANCED SIMULATION MODELING TO EXAMINE THE IMPACT OF INCREASED RESOURCES ON PATIENT THROUGHPUT IN OUTPATIENT CARE
DOES A CLINICAL STUDY REFLECT REAL-LIFE AND REAL-LIFE COSTS
VALIDATION OF EDC VERSIONS OF IBS-QOL, EQ-5D AND WPAI-IBS QUESTIONNAIRES
HEALTH RELATED QUALITY OF LIFE CHANGES IN LAMIVUDINE REFRACTORY CHRONIC HEPATITIS B (CHB) PATIENTS AFTER ENTECAVIR (ETV) OR LAMIVUDINE (LAM) TREATMENT¡V BMS STUDY 026
TEGASEROD SIGNIFICANTLY IMPROVES QUALITY OF LIFE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)
USE OF THRESHOLDS FOR SAFETY REPORTING IN CLINICAL TRIALS
A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF GENETIC TESTING TECHNOLOGIES
INTRODUCTION OF BIAS WHEN USING THE SMEARING RE-TRANSFORMATION METHOD IN THE PRESENCE OF POSITIVELY SKEWED ANTI-LOGGED RESIDUALS
THE USE OF A LIFE ANNUITY TO MORE ACCURATELY CALCULATE MEDICAL COSTS IN A COST-EFFECTIVENESS ANALYSIS
PERSONNEL COSTS, LEARNING CURVES, AND SCALE ECONOMIES FOR TELEPHONE-BASED NURSE INTERVENTIONS
ACCURATE AND RAPID PREDICTION OF DRUG PLAN EXPENDITURE WHILE PLANNING REIMBURSEMENT CHANGES USING POLICY SIMULATION
BRIDGING THE REQUIREMENT-CAPABILITY GAP BETWEEN DRUG PLAN DECISION MAKERS AND THEIR DATA ANALYSTS IN DRUG POLICY PLANNING
PMC8
PMC9
AN INTERNET-BASED EDUCATIONAL INTERVENTION TO INCREASE KNOWLEDGE
WHICH ONE IS LOGICAL? LOGIT OR RARE EVENT LOGIT (RE-LOGIT)
PMC12
VALUE OF ADDING MEDICAL CLAIMS DATA TO THE PHARMACY-BASED MODELS PREDICTING FUTURE HEALTH CARE COSTS AND JUMPS IN COSTS
EQUIVALENCE OF PAPER AND TOUCH SCREEN VERSIONS OF THE EQ-5D VISUAL ANALOG SCALE (EQ-VAS)
INFLUENCE OF VARIOUS HEALTH STATUS MEASURES ON TOTAL EXPENDITURES IN THE MEPS DATASET
LINKING DISEASE-SPECIFIC QUALITY OF LIFE (QOL) SCALES
THE UK EQ-5DINDEX
HEALTH UTILITIES INDEX (HUI) ON-LINE QUESTIONNAIRE SYSTEM
IMPROVING THE SCALING PROPERTIES OF THE PSYCHOLOGICAL GENERAL WELL-BEING SCALE (PGWB)
RELATIONSHIP BETWEEN PATIENT SATISFACTION AND PERCEIVED HEALTH STATUS
DEVELOPING METHODOLOGY FOR THE TRANSLATION AND LINGUISTIC VALIDATION OF PATIENT REPORTED DIARIES
DEVELOPING SYMPTOM-BASED QUESTIONNAIRES FOR DIAGNOSTIC SCREENING
TRANSLATABILITY ASSESSEMENT
POTENTIAL IMPACT OF HEALTH STATUS ON LIFE SATISFACTION AND QUALITY OF LIFE
SELF-ASSESSED HEALTH STATUS IN THE UNITED STATES
INTERPRETING THE MAGNITUDE OF SCORE DIFFERENCES IN THE SF-36 VITALITY SCALE
PATIENTS' PERSPECTIVES OF TREATMENT SATISFACTION
LINGUISTIC VALIDATION OF THE US SPANISH WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE, GENERAL HEALTH VERSION (WPAI:GH)
RECONSIDERING THE PERSPECTIVE IN ECONOMIC EVALUATION
PMC30
AT WHAT COST? A REVIEW OF DRUG ACQUISITION COST ISSUES IN MODELLED ECONOMIC EVALUATIONS.
USING MARKOV MATRICES TO INTEGRATE RISK/BENEFIT CONSIDERATIONS OF HEALTH CARE INTERVENTIONS EVALUATED USING HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS
BRIDGING BEYOND REGRESSION–ARTIFICIAL NEURAL NETWORK IN MAPPING FROM SF-36 TO HEALTH UTILITY
HEALTH CARE AND WORKLOSS COSTS OF OPIOID ABUSE AMONG AN EMPLOYED POPULATION IN THE US
(For abstract PMH2 see page 256)
EMERGENCY DEPARTMENT USE FOR ACUTE ALCOHOL INTOXICATION BY COLLEGE AGE PERSONS
QUALITY-ADJUSTED LIFE YEARS GAINED WITH BUPRENORPHINE TREATMENT FOR OPIATE ADDICTION
COST-EFFECTIVENESS OF ALPRAZOLAM IN ANXIETY DISORDERS
ECONOMIC BURDEN OF GENERALIZED ANXIETY DISORDER (GAD) AND OTHER ANXIETY DISORDERS
DETERMINANTS OF PERMANENT NUSRING HOME ADMISSIONS AMONG ELDERLY IN THE UNITED STATES
THE EFFECT OF VENLAFAXINE, PAROXETINE, AND PLACEBO ON HEALTH-RELATED WORK PRODUCTIVITY IN PANIC DISORDER PATIENTS
A REVIEW OF THE ECONOMIC BURDEN OF ADHD
ESTIMATING THE BUDGET IMPACT OF QUETIAPINE FOR THE TREATMENT OF ACUTE MANIA AMONG HOSPITALIZED PATIENTS
MENTAL HEALTH COST COMPARISON AMONG PATIENTS WITH BIPOLAR DISORDER TREATED WITH RISPERIDONE VERSUS OLANZAPINE OR QUETIAPINE IN A MANAGED CARE SETTING
ANTIPSYCHOTIC USE AND HOSPITALIZATION IN BIPOLAR OR MANIC PATIENTS
PREVALANCE AND COST OF BIPOLAR DISORDER AND TREATMENT WITHIN A MANAGED CARE ORGANIZATION
THE CLINICAL AND ECONOMIC OUTCOMES OF SECOND-GENERATION ANTIDEPRESSANT USE FOR BIPOLAR DISORDER
A CASE-CONTROL STUDY ON SECOND-GENERATION ANTIDEPRESSANT USE IN PATIENTS WITH BIPOLAR DISORDER
STUDY GAPS IN ECONOMIC EVALUATIONS OF PHARMACOTHERAPY IN BIPOLAR DISORDER
MEASURING THE EFFECT OF A POLICY CHANGE IN MONTHLY PRESCRIPTION LIMIT ON HEALTH CARE UTILIZATION AND EXPENDITURE
COMPARING PROPENSITY SCORE AND DIFFERENCE-IN- DIFFERENCE METHODS
AN EXPLORATORY STUDY TO DEVELOP A MODEL OF QUALITY OF LIFE FOR BIPOLAR DISORDER
TREATMENT ADHERENCE WITH ANTIPSYCHOTICS AMONG BIPOLAR AND MANIC PATIENTS
PATTERNS OF DEMENTIA/ALZHEIMER MANAGEMENT AMONG ELDERLY PATIENTS IN US AMBULATORY CARE
COSTS OF DEMENTIA AMONG COMMUNITY DWELLING PATIENTS
PREDICTORS OF HEALTH RELATED QUALITY OF LIFE AMONG DEMENTIA CAREGIVERS
ASSESSING VENLAFAXINE, SERTRALINE, OR PLACEBO TREATMENT ON IMPROVEMENT IN GENERAL LIFE FUNCTIONING AMONG DEPRESSED PATIENTS
IMPROVEMENT OF FATIGUE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH VENLAFAXINE, SERTRALINE, OR PLACEBO
COST AND UTILIZATION DIFFERENCES AMONG CARDIAC PATIENTS TREATED FOR DEPRESSION WITH ZOLOFT VERSUS NO PHARMACEUTICAL TREATMENT
COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN TURKEY
COST-EFFECTIVENESS OF ESCITALOPRAM VS. VENLAFAXIN XR IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN GERMANY
A COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM AND SERTRALINE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
THE EFFECT OF RAISING THREE TIER COPAYMENTS ON SSRI COMPLIANCE RATES
OUTCOME ANALYSIS OF A MULTI-LEVEL INTERVENTION PROGRAM TO IMPROVE ANTIDEPRESSANT MEDICATION ADHERENCE
THE RELATIVE PERFORMANCE OF NEWER ANTIDEPRESSANTS IN A MEDICAID POPULATION
APPROPRIATENESS AND VARIATION IN DRUG UTILIZATION ACROSS PATIENTS WITH DEPRESSION
DRUG UTILIZATION AND MARKET-SHARE COMPETITION AMONG ANTIDEPRESSANT MEDICATIONS IN US MEDICAID PROGRAMS
IMPACT OF RELABELING ON NEFAZODONE PRESCRIBING
THE MAIN AND INTERACTION EFFECTS OF PATIENT AND PHYSICIAN CHARACTERISTICS IN INFLUENCING THE PRESCRIBING OF ANTIDEPRESSANTS
RASCH MODEL COMPARISON OF BECK DEPRESSION INDEX AND MOOD AND ANXIETY SYMPTOMS QUESTIONNAIRE IN MEASUREMENT OF DEPRESSION
A SYSTEMATIC REVIEW OF SUICIDALITY MEASURES IN STUDIES USING SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN CHILDREN AND ADOLESCENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
COMPARING EXHAUSTIVE CHAID CLASSIFICATION TREE AND FORWARD STEPWISE LOGISTIC REGRESSION (LR) IN EXPLAINING THE PRESCRIBING OF ANTIDEPRESSANTS
THE USEFULNESS OF THE EQ-5D IN DIFFERENTIATING AMONG PERSONS WITH MAJOR DEPRESSIVE EPISODE AND ANXIETY
QUALITY-ADJUSTED REMISSION FREE DAYS
QUALITY OF LIFE, EMOTIONAL AND PHYSICAL SYMPTOMS IN DEPRESSION
HOSPITALIZATION AND EMERGENCY ROOM VISITS BEFORE AND AFTER TREATMENT WITH ATYPICAL ANTIPSYCHOTICS
IMPACT OF A PSYCHOEDUCATION PROGRAM ON HEALTH STATUS OF SEVERE AND PERSISTENTLY MENTALLY ILL
PERCEPTION OF SIDE EFFECTS, MEDICATION ADHERENCE AND QUALITY OF LIFE IN PSYCHIATRIC PATIENTS
HISTORY OF SUBSTANCE ABUSE ASSOCIATED WITH POOR PROGNOSIS IN THE TREATMENT OF SCHIZOPHRENIA
RELIABILITY AND VALIDITY OF THE READINESS FOR DISCHARGE QUESTIONNAIRE IN SCHIZOPHRENIA
USE AND COST OF POLYPHARMACY IN SCHIZOPHRENIA
SYSTEMATIC REVIEW ON RELAPSE AND ANTIPSYCHOTIC NON-ADHERENCE IN SCHIZOPHRENIA
ESTIMATING ANNUAL US PREVALENCE OF SCHIZOPHRENIA IN 2002
A PSYCHIATRIC HOSPITAL REVENUE AND PROFITABILITY MODEL FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA IN JAPAN
COST-EFFECTIVENESS EVALUATION OF LONG-ACTING RISPERIDONE
THE COST OF RELAPSE IN SCHIZOPHRENIA IN THE UNITED STATES
DIRECT HEALTH CARE COSTS OF SCHIZOPHRENIA IN THE UNITED STATES
DIFFERENTIAL RISKS AND ASSOCIATED COSTS OF HOSPITALIZATION DURING ANTIPSYCHOTIC TREATMENT IN MEDICAID PATIENTS WITH SCHIZOPHRENIA
CLASSIFYING ANTIPSYCHOTIC ADHERENCE USING LATENT CLASSES ANALYSIS
STARTING DOSE AND PERSISTENCE FOR ZIPRASIDONE USERS IN MEDICAID
ELECTRONIC MONITORING OF ANTIPSYCHOTIC ADHERENCE OF OUTPATIENTS WITH SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER AND ASSOCIATION WITH SYMPTOMS, QUALITY OF LIFE AND COGNITION
THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY—E-STAR
THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY—E-STAR
THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY—E-STAR
COMPARISON OF OUTCOMES REPORTED BY INDIVIDUALS WITH SCHIZOPHRENIA RESIDING IN THE COMMUNITY AND OBJECTIVE OUTCOMES REPORTED BY CAREGIVERS
VALUATION OF SCHIZOPHRENIA-RELATED HEALTH STATES BY THE GENERAL POPULATION USING THE AQOL, TIME TRADE-OFF AND VISUAL ANALOGUE SCALES
GREATER DEPRESSIVE SYMPTOMS ARE ASSOCIATED WITH WORSE FUNCTIONAL OUTCOMES IN PATIENTS DIAGNOSED WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER
USE OF THE CAREGIVER STRAIN QUESTIONNAIRE IN AN INTERNATIONAL STUDY
IMPACT OF ATYPICAL AGENTS ON OUTCOMES OF CARE IN SCHIZOPHRENIC PATIENTS
INCREMENTAL DIRECT COST OF BACK PAIN IN THE UNITED STATES IN 2001
EVALUATION OF AN AUTOMATED SYSTEM FOR PRIOR AUTHORIZATION—A COX-2 INHIBITOR EXAMPLE
COMPARISON OF WEIGHT REDUCTION AND SATISFACTION OF ORLISTAT AND SIBUTRAMINE
RECENT TRENDS AND A FUTURE FORECAST OF POPULATION BODY MASS INDEX LEVELS IN THE UNITED KINGDOM
PREVALENCE TRENDS OF OVERWEIGHT AND OBESITY AND TREATMENT PATTERNS FOR WEIGHT CONTROL IN THE US POPULATION
RELIABLE MEASUREMENT OF OBESITY
COST EFFECTIVENESS OF SIBUTRAMINE IN THE LONG-TERM OUTCOMES OF SIBUTRAMINE EFFECTIVENESS ON WEIGHT STUDY
COSTS OF OBESITY IN THE UNITED STATES AND EUROPE
LIFETIME COSTS ASSOCIATED WITH OBESITY
USING A BUDGET IMPACT MODEL TO PREDICT FIRST-YEAR USE OF A NEW OSTEOPOROSIS THERAPY
ALENDRONATE AND HORMONE REPLACEMENT THERAPY (HRT) IN THE PREVENTION OF OSTEOPOROTIC FRACTURE IN THE DEPARTMENT OF DEFENSE (DOD)
COST-EFFECTIVENESS ANALYSIS OF BIPHOSPHONATES AND RALOXIFENE FOR TREATMENT OF OSTEOPOROSIS AND PREVENTION OF FRACTURES
FACTORS AFFECTING THE BONE DENSITY TEST PRESCRIBING FOR OSTEOPOROSIS IN MALE AMBULATORY PATIENTS
POST-OSTEOPOROTIC FRACTURE DRUG TREATMENT FOR OSTEOPOROSIS IN NURSING HOME ELDERLY
IMPACT OF AN OSTEOPOROSIS INTERVENTION PROGRAM OF PATIENTS WITH A FRACTURE HISTORY
VALIDATION STUDY OF THE OSTEOPOROSIS PATIENT SATISFACTION QUESTIONNAIRE (OPSAT-Q)
REDUCING MORTALITY IN PATIENTS WITH SUBSTANCE ABUSE AND CHRONIC NON-MALIGNANT PAIN THROUGH A MULTIDISCIPLINARY OPIOID RENEWAL CLINIC
EVALUATION OF THE DIRECT COSTS OF PURE NEUROPATHIC PAIN MANAGEMENT IN FRANCE BEFORE A FIRST CONSULTATION IN A PAIN MANAGEMENT CENTER
SUMMARY OF HOSPITAL LOGISTICS ASSOCIATED WITH INTRAVENOUS PATIENT-CONTROLLED ANALGESIA (IV PCA) FOR ACUTE POSTOPERATIVE PAIN MANAGEMENT
PARENTS' PERCEPTION OF THE SAFETY OF PEDIATRIC NON-PRESCRIPTION DRUGS—ACETAMINOPHEN AS AN EXAMPLE
TYPES OF PROBLEMS ASSOCIATED WITH INTRAVENOUS PATIENT-CONTROLLED ANALGESIA (IV PCA) INFUSION PUMPS
RETROSPECTIVE ANALYSIS OF DRUG UTILIZATION PATTERNS IN CANCER AND NON-CANCER PATIENTS TREATED WITH TRANSDERMAL BUPRENORPHINE AND TRANSDERMAL FENTANYL
CONFIRMATORY FACTOR ANALYSIS OF THE BECK DEPRESSION INVENTORY
DEVELOPMENT OF DIFFERENT LANGUAGE VERSIONS OF A US BACK PAIN QUESTIONNAIRE
SEVERE PAIN IN PERSONS WHO RECEIVED HOSPICE CARE IN THE UNITED STATES (US)
PATIENT SATISFACTION WITH PAIN MANAGEMENT 28 DAYS AFTER TOTAL KNEE ARTHROPLASTY
SELECTED OUTCOMES IN PATIENTS WITH OVERACTIVE BLADDER COMPARED TO NON-OVERACTIVE BLADDER CONTROLS
THE COST-EFFECTIVENESS OF SUBSTITUTING DARBAPOETIN FOR EPOETIN
AN ECONOMIC MODEL OF OVERACTIVE BLADDER TREATMENT PERSISTENCE
A COMPARISON OF TOTAL DIRECT MEDICAL COSTS AMONG PATIENTS RECEIVING AGENTS USED IN THE PHARMACOLOGIC MANAGEMENT OF OVERACTIVE BLADDER
ECONOMIC EVALUATION OF EVEROLIMUS WITH REDUCED- DOSE CYCLOSPORINE IN DE NOVO RENAL TRANSPLANT RECIPIENTS
A PHARMACOECONOMIC EVALUATION OF OXYBUTYNIN AND TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER
ESTIMATING THE COST SAVINGS DUE TO THE EFFECT OF KREMEZIN IN DELAYING THE ONSET OF RECEIVING DIALYSIS TREATMENTS AMONG PATIENTS WITH CHRONIC RENAL FAILURE
THE DIRECT COSTS OF STRESS URINARY INCONTINENCE TREATMENT AMONG WOMEN IN A MEDICAID POPULATION
INTERSTITIAL CYSTITIS COSTS, TREATMENT AND COMORBIDITIES IN AN EMPLOYED POPULATION
EPOETIN ALFA AND DARBEPOETIN ALFA DOSING TRENDS IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS
ADHERENCE TO EXTENDED RELEASE TOLTERODINE VERSUS IMMEDIATE- AND EXTENDED-RELEASE OXYBUTYNIN AMONG COMMERCIALLY-INSURED PATIENTS WITH OVERACTIVE BLADDER
ADHERENCE WITH MEDICATIONS USED TO TREAT OVERACTIVE BLADDER IN A MANAGED CARE POPULATION.
PREDICTORS OF MEDICATION ADHERENCE AND ASSOCIATED HEALTH CARE COSTS IN AN OLDER POPULATION WITH DETRUSOR OVERACTIVITY
FACTORS INFLUENCING THE ROUTE OF ADMINISTRATION FOR EPOETIN TREATMENT AMONG U.S. HEMODIALYSIS PATIENTS
IMPACTS OF IMPLEMENTING CASE PAYMENT SYSEM TO HEMODIALYSIS OF MEDICAL AID PATIENTS ON DIALYSIS FREQUENCIES AND EXPENDITURE IN KOREA
DOSING PATTERNS OF ERYTHROPOIETIC AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE
PREVALENCE, DEMOGRAPHICS, AND PHARMACOLOGICAL TREATMENT PATTERNS OF OVERACTIVE BLADDER IN A MANAGED CARE POPULATION
EVALUATION OF THE RELIABILITY AND VALIDITY OF THE INCONTINENCE QUALITY OF LIFE QUESTIONNAIRE (I-QOL) IN PATIENTS WITH DETRUSOR HYPERREFLEXIA
ESTABLISHING THE CONTENT VALIDITY OF THE URINARY SENSATION SCALE (USS)
PATIENT SELECTION CRITERIA IMPACTS OUTCOMES IN A RETROSPECTIVE OAB STUDY
DEGREE OF SYMPTOM BOTHER IN URINARY INCONTINENCE
DISCLOSURE INFORMATION